GlassScriptPhysician profile
Vanessa Darnell
NPI 1679806137
$2,145.19
in general payments reported to CMS, 2019-2025
18 companies · $593 in 2025
The $593 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2023: $277 · 2024: $982 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Education: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.65 |
| Education | $367.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $505.71 | 2023-2025 | Veozah |
| Abbvie INC. | $403.05 | 2024-2025 | |
| Novo Nordisk INC | $300.22 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Kci USA, INC. | $276.14 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $219.82 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $75.14 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $72.18 | 2023-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $69.19 | 2023-2025 | |
| Glaxosmithkline, LLC. | $60.33 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $29.17 | 2024-2025 | Trintellix |
| Pfizer INC. | $20.53 | 2024 | |
| Axsome Therapeutics, INC. | $18.99 | 2025 | Auvelity |
| Smith+Nephew, INC. | $17.41 | 2021 | |
| Sumitomo Pharma America, INC. | $17.27 | 2025 | Gemtesa |
| Ascendis Pharma Endocrinology INC | $15.84 | 2025 | Yorvipath |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $15.64 | 2025 | Aristada, Lybalvi |
| Lundbeck LLC | $14.33 | 2025 | Rexulti |
| Tempus Ai, INC | $14.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Darnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.